(Q43440505)

23 November 2017

title

CCAFU Recommendations 2013: Prostate cancer (English)

1 reference

23 November 2017

15

1 reference

23 November 2017

L Salomon

1

1 reference

23 November 2017

C Bastide

2

1 reference

23 November 2017

P Beuzeboc

3

1 reference

23 November 2017

L Cormier

4

1 reference

23 November 2017

G Fromont

5

1 reference

23 November 2017

C Hennequin

6

1 reference

23 November 2017

P Mongiat-Artus

7

1 reference

23 November 2017

M Peyromaure

8

1 reference

23 November 2017

G Ploussard

9

1 reference

23 November 2017

R Renard-Penna

10

1 reference

23 November 2017

F Rozet

11

1 reference

23 November 2017

D Azria

12

1 reference

23 November 2017

P Coloby

13

1 reference

23 November 2017

V Molinié

14

1 reference

23 November 2017

X Rebillard

16

1 reference

23 November 2017

P Richaud

17

1 reference

23 November 2017

A Villers

18

1 reference

23 November 2017

M Soulié

19

1 reference

23 November 2017

Les membres du CCAFU

20

1 reference

23 November 2017

language of work or name

French

0 references

publication date

1 November 2013

1 reference

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

23 November 2017

published in

1 reference

23 November 2017

volume

23 Suppl 2

1 reference

23 November 2017

page(s)

S69-101

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Gleason grading: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Staging of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Multiparametric ultrasound of the prostate: adding contrast enhanced ultrasound to real-time elastography to detect histopathologically confirmed cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

ESUR prostate MR guidelines 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

The prevention of prostate cancer--the dilemma continues

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Chemoprevention of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Recommandations en Onco-Urologie 2010 : Cancer de la prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate-cancer mortality at 11 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Early detection of prostate cancer: European Association of Urology recommendation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

1 reference

7 January 2021

Implications of the International Society of Urological Pathology modified Gleason grading system

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

1 reference

7 January 2021

Radical prostatectomy versus observation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Active surveillance for the management of prostate cancer in a contemporary cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Medium-term outcomes of active surveillance for localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

A multi-institutional evaluation of active surveillance for low risk prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Robot-assisted radical prostatectomy compared with open and laparoscopic approaches: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Extrafascial versus interfascial nerve-sparing technique for robotic-assisted laparoscopic prostatectomy: comparison of functional outcomes and positive surgical margins characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Bilateral vs unilateral laparoscopic intrafascial nerve-sparing radical prostatectomy: evaluation of surgical and functional outcomes in 457 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Role of androgen deprivation therapy for node-positive prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Implementing intensity modulated radiotherapy to the prostate bed: dosimetric study and early clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

[Association of radiotherapy and hormonotherapy in locally advanced prostate cancer]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate brachytherapy: indications and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Primary and salvage cryotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Intermittent androgen suppression for rising PSA level after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Intermittent versus continuous androgen deprivation in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Incidence and mortality of incidental prostate cancer: a Swedish register-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Incidental carcinoma of the prostate: an analysis of the predictors of progression

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Management of stage A prostate cancer with a high probability of progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

An analysis of watchful waiting for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Early outcomes of active surveillance for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Insignificant prostate cancer and active surveillance: from definition to clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Pathological outcomes of candidates for active surveillance of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate cancer mortality following active surveillance versus immediate radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Indications and contraindications for nerve-sparing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

[Surgical margins after radical prostatectomy: technical aspects and prognostic value]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Intermediate- and high-risk prostate cancer: a plea for high-dose, high-precision intensity-modulated radiotherapy with a modulated duration of androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Developing guidelines for chronic kidney disease: we should include all of the outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

[Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Cryotherapy for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Cryotherapy for prostate cancer: ready for prime time?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Duration of androgen suppression in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

1 reference

7 January 2021

Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

[A review of bone scintigraphy in metastases from urological malignancies in adults]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Molecular imaging of prostate cancer: PET radiotracers

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Salvage radiation in men after prostate-specific antigen failure and the risk of death

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

[Salvage radical prostatectomy after external radiotherapy for prostate cancer: indications, morbidity and results. Review from CCAFU prostate section].

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Salvage Radiotherapy After High-Intensity Focussed Ultrasound for Recurrent Localised Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2813%2970048-4

7 January 2021

10.1016/S1166-7087(13)70048-4

Identifiers

DOI

1 reference

23 November 2017

1 reference